How metabolite evidence can support qualification of a non-mutagenic pharmaceutical impurity.
If an impurity is a known metabolite of the API, existing exposure to that metabolite can be highly relevant to qualification. However, the identity and magnitude of metabolic exposure must be interpreted carefully.
Confirm identity
The impurity should be confidently linked to the metabolite rather than inferred from a vague structural resemblance.
Compare exposure
The exposure to the metabolite in clinical or non-clinical studies should be compared with the proposed impurity exposure.
Species relevance
Animal metabolite evidence can be informative, but relevance to humans and the target population should be discussed.
Residual uncertainty
Metabolite status does not automatically address every endpoint or every exposure scenario.
Frequently asked questions
Is every metabolite automatically qualified?
No.
Why compare exposure levels?
Because qualification depends on whether prior exposure adequately covers the proposed impurity level.
Can animal metabolites support the assessment?
Yes, when their relevance is scientifically justified.
Does metabolite evidence replace mutagenicity assessment?
Mutagenicity should be appropriately addressed under the applicable framework.
